Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	6/22/2007 12:35:58 AM
	of 10280

Sepracor "outperform" Tuesday, June 19, 2007 2:52:17 AM ET Robert W. Baird NEW YORK, June 19 (newratings.com) - Analysts at Robert W Baird maintain their "outperform" rating on Sepracor Inc (SEPR.NAS). The 12-month target price is set to $67. In a research note published yesterday, the analysts mention that the new Medicare Xopenex UDV reimbursement rate, which is scheduled to be effective from July 1, has been set at $1.31 per unit dose, which is almost half of the anticipated rate of $2.50-$2.75. Sepracor could exit this market segment, since the reduced bundled reimbursement rate may make it unviable for the company, the analysts say. Robert W Baird adds, however, that there could be a delay in the implementation of the new rates, given press reports about continued negotiations with the CMS.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next